GlassScriptPhysician profile
Ira Gurland
NPI 1730159476
$638.19
in general payments reported to CMS, 2019-2025
11 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.04 · 2020: $139 · 2021: $36.06 · 2022: $128 · 2023: $48.37 · 2024: $35.78 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $270.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $195.84 | 2020-2022 | |
| Organogenesis INC. | $90.64 | 2019-2022 | |
| Insmed, INC. | $76.81 | 2025 | Arikayce, Brinsupri |
| Smith+Nephew, INC. | $71.03 | 2019-2023 | Regranex, Collagenase Santyl |
| Merck Sharp & Dohme LLC | $70.79 | 2019-2025 | Pifeltro |
| Viiv Healthcare Company | $35.78 | 2024 | Cabenuva |
| Melinta Therapeutics, LLC | $25.10 | 2019-2020 | |
| Kerecis Limited | $19.00 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Shionogi INC | $18.72 | 2025 | Fetroja |
| Invivyd INC | $18.40 | 2025 | Pemgarda |
| Theratechnologies INC. | $16.08 | 2025 | Egrifta, Trogarzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Gurland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.